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Introduction
============

Severe sepsis and septic shock are common diseases in ICUs, with high mortality rates \[[@B1],[@B2]\]. According to more recent data from the Statistical Federal Office in Germany, there were 88,000 patients with severe sepsis or septic shock in 2011 in German hospitals, with associated hospital mortality rates of 43% for severe sepsis and 60% for septic shock, respectively \[[@B3]\]. To overcome this high mortality, an adequate antimicrobial therapy starting at an early stage is mandatory. To guide such a therapy, the most promising parameters appear to be plasma levels of procalcitonin (PCT) \[[@B4]\]. Besides PCT, no other sepsis biomarker has achieved universal use throughout different healthcare settings in Germany and neighboring Europe in the last decade. High PCT concentrations are typically found in bacterial infection, in contrast to lower levels in viral infection and levels below 0.1 ng/mL in patients without infection \[[@B5]\]. Furthermore, serum PCT concentrations are positively correlated with the severity of infection. Thus, adequate antibiotic treatment leads to decreasing PCT levels \[[@B5]\].

Recent reviews focused on PCT-based algorithms in patients with infections in general \[[@B6],[@B7]\], respiratory tract infections \[[@B8],[@B9]\], or patients treated in the ICU \[[@B10]-[@B13]\]. These reviews focused on different patients in different settings with different treatment algorithms. Most of them included critically ill patients with different disease severity ranging from suspected infection to pneumonia or sepsis \[[@B10]-[@B13]\]. The others comprised even more patients of different settings: patients with various diseases such as sepsis, bronchitis, and respiratory tract infection, in various settings (primary care, emergency department, ICU, and inpatient wards) were combined in one review \[[@B6],[@B7]\]. Two reviews focused only on patients with respiratory tract infection \[[@B8],[@B9]\]. However there is no review exclusively including the population of ICU patients with severe sepsis or septic shock: both entities are hereinafter collectively referred to severe sepsis. Our meta-analysis addresses two essential research questions: 1) does a PCT-guided strategy to determine the duration of antimicrobial therapy reduce antibiotic use compared with a strategy not based on PCT? 2) Does such a PCT-guided strategy improve health outcomes compared with a strategy not based on PCT? \[[@B14]\]. As evidence for the effect of PCT-guided therapy in severe sepsis is missing, we investigated the effect of PCT-guided therapy compared to standard care.

Materials and methods
=====================

The systematic review was performed following current guidelines and is reported according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement \[[@B15],[@B16]\].

Literature search and data extraction
-------------------------------------

Two reviewers (AP, CW) independently performed a systematic search in the databases Medline via PubMed, Excerpta Medica database (Embase), ISI Web of Knowledge including the databases Web of Science, Journal Citation Reports and Science Citation Index (SCI). Furthermore, searches in BioMed Central, ScienceDirect and the Cochrane Central Register of Controlled Trials were continued. To identify unpublished or ongoing studies and to obtain the study protocols we searched two further websites (<http://www.ClinicalTrials.gov> and <http://www.ISRCTN.org>). The following keywords or medical subject headings (MeSH) were used: "procalcitonin" or "PCT" combined with "sepsis" or "SIRS" or "systemic inflammatory response syndrome" or "bacterial infection". All databases had been searched up to 14 June 2013.

All primary intervention studies were included that compared PCT-guided therapy with standard care according to current guidelines that met the following inclusion criteria: 1) studies that assessed the efficacy of a treatment algorithm based on procalcitonin; 2) studies that had a well-defined standard for the target condition (severe sepsis), which included the use of definitions according to the American College of Chest Physicians (ACCP)/Society of Critical Care Medicine (SCCM) Consensus Conference \[[@B17]\] and the German Sepsis Society \[[@B18]\]; and 3) studies that provided sufficient information to calculate the relative risk (RR) together with 95% CI or the hazard ratio (HR) together with 95% CI respectively.

Eligible studies had to be randomized controlled clinical trials (RCTs) or prospective cohort studies. Studies dealing with neonates were excluded, because of considerable differences in diagnosis, course and therapy of sepsis compared to adults. The published language was not restricted. Disagreements of judgment and inclusion of studies were solved by consensus.

Data were extracted using a structured data collection sheet including the following items: authors and year of study, design, setting, diagnosis, procalcitonin test, randomization, number and characteristics of participants, interventions, outcomes, duration, availability of study protocol, and country. Primary outcomes of this meta-analysis were 28-day mortality and hospital mortality. Secondary outcomes were duration of antimicrobial therapy, length of stay in the ICU and length of stay in the hospital. If additional information was needed, the authors of the studies were contacted by Email. Eligible studies with insufficient data for calculation or missing replies from the authors were excluded.

Risk of bias
------------

For assessing risk of bias, we applied the Cochrane Collaboration tool for assessing risk of bias by judging seven items representing sources of risk of bias \[[@B19]\]. The following items were evaluated: sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. The classification of the assessment was: low risk of bias, high risk of bias, or uncertain risk of bias. The assessment was done independently by two reviewers (AP, CW). Disagreements were resolved by consensus.

Statistical analysis
--------------------

The statistical calculations were done with the freely available software R \[[@B20]\] using the R package meta \[[@B21]\]. Results were presented graphically using forest plots. As a meta-analysis is an observational study, the statistical analysis covered the investigation of bias and heterogeneity. A formal analysis of publication bias was based on Egger's test \[[@B22]\]. For dichotomous outcomes (for example, hospital mortality) RRs were calculated for every single study by means of 2 × 2 contingency tables. The calculation of combined estimates was performed using the Mantel-Haenszel method. For continuous outcomes (for example, length of antibiotic treatment) HRs based on the exponential distribution were calculated together with their variances \[[@B23]\]. This approach was chosen because the necessary information for the calculation of standardized mean differences was not available. Thus, the length of stay and antibiotic therapy were modeled using the exponential distribution. This approach was chosen rather than the standardized differences because it can be used if only the mean duration is reported in the respective study. Summary estimates were obtained using the inverse variance method.

Heterogeneity was assessed using the Cochran *Q*-test and the *I*^2^ measure \[[@B24]\]. The heterogeneity variance tau^2^ was calculated using the moment estimator of DerSimonian-Laird \[[@B25]\]. For all outcomes the fixed effect model as well as the random effects model was applied. Outliers and influential studies were investigated using case-deletion techniques analysis in order to identify studies with great impact on the overall results.

Results
=======

Literature search
-----------------

We identified 9,071 records by searching the databases PubMed, Embase, ISI Web of Knowledge, BioMed Central, ScienceDirect and the Cochrane Central Register of Controlled Trials. After removing 5,602 duplicates, the titles and abstracts of the remaining 3,469 records were screened. Therefore 3,360 records could be excluded. By assessing the full-text articles of the remaining 109 records, 7 studies \[[@B26]-[@B32]\] fulfilled the inclusion criteria and were thus eligible for our meta-analysis (Figure [1](#F1){ref-type="fig"}). Furthermore, we identified 7 ongoing studies registered at <http://www.ClinicalTrials.gov> that might deliver important results for future meta-analyses.

![**Preferred reporting items for systematic reviews and meta-analyses** (**PRISMA) flow diagram.** Study identification and selection process. SIRS, systemic inflammatory response syndrome; ACCP, American College of Chest Physicians; SCCM, Society of Critical Care Medicine; PCT, procalcitonin. \*, available online at <http://www.ClinicalTrials.gov>.](cc13157-1){#F1}

We excluded two studies due to insufficient information and missing replies \[[@B33],[@B34]\].

The study from Bagnenko *et al*. \[[@B34]\] was excluded because of missing data and deficits in quality: the inclusion of patients was not clearly described, the exact number of patients treated in each group was not given, for hospital mortality only percentages without absolute numbers were reported, and finally the treatment regimen for the control group was not specified. The authors did not respond to clarify these questions. Another study had to be excluded, because information of a subgroup of 25 patients with sepsis was missing \[[@B33]\]. Again, the authors did not respond to clarify these questions. In particular we tried to obtain the data for all septic patients included in two trials \[[@B27],[@B29]\]. In one case, further information was provided \[[@B29]\], in another the authors did not pass on any further information, so we could only include the patients with septic shock from this study \[[@B27]\].

Publication bias
----------------

As only seven studies were included in the meta-analysis, assessment of publication bias using a funnel plot, followed by a linear regression test of funnel plot asymmetry (Egger's test) \[[@B22]\], was not possible.

Study characteristics
---------------------

All eligible studies were published in the English language. Because no cohort study met the inclusion criteria, the meta-analysis only consists of RCTs. All studies were conducted in Europe between 2003 \[[@B32]\] and 2009 \[[@B26]\]. Four studies were conducted in mixed surgical/medical ICUs \[[@B26],[@B27],[@B29],[@B30]\], and three studies were conducted in surgical ICUs without medical patients \[[@B28],[@B31],[@B32]\]. The number of included patients from each study ranged from 27 \[[@B31]\] to 459 \[[@B29]\] with a total number of 1,075 patients. In two studies the subgroup of septic patients was included \[[@B27],[@B29]\].

For PCT measurements three different PCT tests were used: Brahms PCT Kryptor \[[@B26],[@B27],[@B29],[@B30]\], Brahms PCT LIA \[[@B28],[@B31]\] and Brahms PCT-Q \[[@B32]\]. The main focus in the PCT-guided therapy was on de-escalation in three studies \[[@B28],[@B30],[@B31]\], on de-escalation as well as escalation in two studies \[[@B26],[@B27]\], and mainly on escalation in two studies \[[@B29],[@B32]\]. A summary of study characteristics and treatment algorithms of the eligible studies is shown in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

###### 

Characteristics of included studies

  **Study**                                     **Annane*et al.*2013**\[[@B26]\]         **Bouadma*et al.*2010**\[[@B27]\]         **Hochreiter*et al.*2009**\[[@B28]\]   **Jensen*et al.*2011**\[[@B29]\]   **Nobre*et al.*2008**\[[@B30]\]   **Schroeder*et al.*2009**\[[@B31]\]   **Svoboda*et al.*2007**\[[@B32]\]
  -------------------------------------------- ---------------------------------- ----------------------------------------------- -------------------------------------- ---------------------------------- --------------------------------- ------------------------------------- -----------------------------------
  **Design**                                                  RCT                                       RCT                                        RCT                                  RCT                                RCT                                 RCT                                  RCT
  **Setting**                                       Surgical and medical ICU                 Surgical and medical ICU                          Surgical ICU                   Surgical and medical ICU          Surgical and medical ICU                  Surgical ICU                         Surgical ICU
  **Condition**                                  Severe sepsis and septic shock                    Septic shock                               Severe sepsis                Severe sepsis and septic shock    Severe sepsis and septic shock               Severe sepsis                        Severe sepsis
  **Total number of included patients**                        61                                       267                                        110                                  459                                79                                  27                                   72
  **Number of patients**                                                                                                                                                                                                                                                                              
  PCT group/control group                                    31/30                            138/129 (septic shock)                              57/53                               247/212                             39/40                               14/13                                38/34
  55/53 (positive blood culture)                                                                                                                                                                                                                                                    
  **Hospital mortality**                                                                                                                                                                                                                                                                              
  Relative risk (95% CI)                               0.68 (0.30; 1.55)                                NA                                  1.00 (0.53; 1.86)                            NA                         1.03 (0.46; 2.31)                   0.93 (0.23; 3.81)                           NA
  Events PCT group/events control group                       7/10                                     15/14                                       9/9                                  3/3                                                                                         
  **28-day mortality**                                                                                                                                                                                                                                                                                
  Relative risk (95% CI)                                       NA                                1.15 (0.81; 1.63)                                  NA                           1.02 (0.80; 1.30)                  1.03 (0.43; 2.46)                          NA                            0.69 (0.35; 1.36)
  Events PCT group/events control group               48/39 (septic shock)                             90/76                                       8/8                                 10/13                                                                                        
  **Duration of antibiotic treatment, days**                                                                                                                                                                                                                                                          
  PCT group/control group                                 5/5 (median)             9.8/12.8 (mean) (only positive blood culture)              5.9/7.9 (mean)                             NA                         6.0/9.5 (median)                     6.6/8.3 (mean)                             NA
  **Length of ICU stay, days**                                                                                                                                                                                                                                                                        
  PCT group/control group                                22/23 (median)                                 NA                                   15.5/17.7 (mean)                     6.0/5.0 (median)                  4.0/7.0 (median)                    16.4/16.7 (mean)                     16.1/19.4 (mean)
  **Length of hospital stay, days**                                                                                                                                                                                                                                                                   
  PCT group/control group                                27/33 (median)                                 NA                                          NA                           23.0/22.0 (median)                17.0/23.5 (median)                          NA                                   NA
  **SOFA score**                                                                                                                                                                                                                                                                                      
  PCT group/control group                               9.5/10 (median)                                 NA                                    6.7/7.0 (mean)                             NA                          6.4/6.6 (mean)                      7.3/8.3 (mean)                       7.9/9.3 (mean)
  8.5 to 11/8 to 11 (IQR)                                3.68/3.62 (SD)                            3.3/3.0 (SD)                                3.5/4.2 (SD)                         2.8/3.3 (SD)                                                                                    
  **Medical patients, %\***                                   97%                                       89%                                         0%                                  59%                                NA                                  0%                                   0%
  **Subgroup of study**                                        No                                       Yes                                         No                                  Yes                                No                                  No                                   No
  **Duration of study, months**                                36                                       12                                          15                                   29                                15                                   7                                   29
  **Study protocol available**                                Yes                                       Yes                                        Yes                                  Yes                                Yes                                 No                                   No
  **Country**                                                France                                   France                                     Germany                              Denmark                          Switzerland                           Germany                          Czech Republic

PCT, procalcitonin; RCT, randomized controlled clinical trial; SOFA, sequential organ failure assessment; NA, data were not available; \*data were stated in study or calculated from information given in study.

###### 

PCT assays and algorithms used for procalcitonin (PCT)-guided treatment in the included studies

  **Study**                                                                                                                                             **PCT test**         **Regimen in the PCT group**                                                                                              **Regimen in the control group**
  ----------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- ------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------
  **Annane*et al.*2013**\[[@B26]\]                                                                                                                      Brahms PCT Kryptor   **Medical patients:**                                                                                                     Antibiotic treatment at the discretion of the patient's physician
  PCT \<0.25 ng/mL: antibiotics not initiated or stopped                                                                                                                                                                                                                                               
  PCT ≥ 0.25 and \< 0.5 ng/mL: Antibiotics strongly discouraged                                                                                                                                                                                                                                        
  PCT ≥0.5 and \<5 ng/mL: antibiotics recommended                                                                                                                                                                                                                                                      
  PCT ≥5 ng/mL: antibiotics strongly recommended                                                                                                                                                                                                                                                       
  **Surgical patients:**                                                                                                                                                                                                                                                                               
  PCT \<4 ng/mL: antibiotics not initiated or stopped                                                                                                                                                                                                                                                  
  PCT ≥4 and \<9 ng/mL: antibiotics recommended                                                                                                                                                                                                                                                        
  PCT ≥9 ng/mL: antibiotics strongly recommended                                                                                                                                                                                                                                                       
  **Bouadma*et al.*2010**\[[@B27]\]                                                                                                                     Brahms PCT Kryptor   **Guidelines for starting of antibiotics:**                                                                               Treatment according to international and local guidelines
  PCT \<0.25 ng/mL: antibiotics strongly discouraged                                                                                                                                                                                                                                                   
  PCT ≥0.25 and \<0.5 ng/mL: antibiotics discouraged                                                                                                                                                                                                                                                   
  PCT ≥0.5 and \<1 ng/mL: antibiotics encouraged                                                                                                                                                                                                                                                       
  PCT ≥1 ng/mL: antibiotics strongly encouraged                                                                                                                                                                                                                                                        
  **Guidelines for continuing or stopping of antibiotics:**                                                                                                                                                                                                                                            
  PCT \<0.25 ng/mL: stopping of antibiotics strongly encouraged.                                                                                                                                                                                                                                       
  Decrease by ≥80% from peak concentration, or concentration ≥0.25 and \<0.5 ng/mL: stopping of antibiotics encouraged                                                                                                                                                                                 
  Decrease by \<80% from peak concentration and concentration ≥0.5 ng/mL: continuing of antibiotics encouraged                                                                                                                                                                                         
  Increase of concentration compared with peak concentration and concentration ≥0.5 ng/mL: changing of antibiotics strongly encouraged                                                                                                                                                                 
  **Hochreiter*et al.*2009**\[[@B28]\]                                                                                                                  Brahms PCT LIA       PCT \< 1 ng/mL: Antibiotics discontinued.                                                                                 Antibiotic treatment according to standard regimen over 8 days
  PCT \>1 ng/mL and dropped to 25 to 35% of the initial value over 3 days: antibiotics discontinued                                                                                                                                                                                                    
  Additionally the infection had to improve clinically                                                                                                                                                                                                                                                 
  **Jensen*et al.*2011**\[[@B29]\]                                                                                                                      Brahms PCT Kryptor   Single baseline measurement of PCT ≥1.00 ng/mL or PCT ≥1.00 ng/mL and not decreased at least 10% from the previous day:   Antibiotic treatment according to current guidelines
  1\) increasing the antimicrobial spectrum covered                                                                                                                                                                                                                                                    
  2\) intensifying the diagnostic effort to find uncontrolled sources of infection                                                                                                                                                                                                                     
  PCT \<1.00 ng/mL for at least 3 days: de-escalation possible                                                                                                                                                                                                                                         
  **Nobre*et al.*2008**\[[@B30]\]                                                                                                                       Brahms PCT Kryptor   Patients with PCT \<1 ng/mL re-evaluated at day 3: antibiotics discontinued if PCT \<0.1 ng/mL                            Antibiotic treatment based on empirical rules
  Patients with PCT ≥1 ng/mL re-evaluated at day 5: antibiotics discontinued if PCT dropped \>90% from the baseline peak level or if PCT \<0,25 ng/mL                                                                                                                                                  
  **Schroeder*et al.*2009**\[[@B31]\]                                                                                                                   Brahms PCT LIA       PCT \<1 ng/mL and clinical signs of infection improved: antibiotics discontinued                                          Antibiotic treatment according to clinical signs and empiric rules
  PCT dropped to \<35% of the initial concentration within 3 days and clinical signs of infection improved: antibiotics discontinued                                                                                                                                                                   
  **Svoboda*et al.*2007**\[[@B32]\]                                                                                                                     Brahms PCT-Q         PCT \>2 ng/mL: change of antibiotics and catheters                                                                        Treatment according to contemporary treatment protocol of the institute
  PCT ≤2 ng/mL: ultrasonography and/or computer tomography followed by repeated surgical treatment if localized infection was confirmed                                                                                                                                                                

PCT, procalcitonin.

Risk of bias
------------

The overall risk of bias was moderate according to the Cochrane Collaboration tool for assessing risk of bias of all included studies. Two studies achieved low overall risk of bias \[[@B27],[@B32]\], whereas the remaining studies had moderate overall risk of bias \[[@B26],[@B28]-[@B31]\]. Two items had low risk of bias in all studies: "incomplete outcome data" and "other bias". Oftentimes the risk of bias remained unclear due to insufficient information given in each study.

Figure [2](#F2){ref-type="fig"} summarizes the risk of bias of included studies. Detailed information about risk of bias, support for judgment of bias and graphically summarized information on risk of bias are given in the online supplement (Additional files [1](#S1){ref-type="supplementary-material"} and [2](#S2){ref-type="supplementary-material"}).

![**Risk of bias summary.** Cochrane Collaboration tool for assessing risk of bias. Review authors' judgments about each risk of bias item for each included study. +, low risk of bias; -, high risk of bias; ?, unclear risk of bias.](cc13157-2){#F2}

Combined estimates
------------------

### Primary outcomes

Hospital mortality in severe sepsis patients was reported in four studies \[[@B26],[@B28],[@B30],[@B31]\]. The combined estimate of the RR based on the fixed-effect model for hospital mortality is 0.91 (95% CI: 0.61; 1.36) (Figure [3](#F3){ref-type="fig"}), with no differences between the PCT-guided therapy and standard-care group. The test of heterogeneity showed no significant heterogeneity between these studies (*Q* = 0.66; df = 3; *I*^2^ = 0%; tau^2^ = 0; *P* = 0.8835).

![**Forest plot - hospital mortality.** The forest plot represents the relative risk (RR) together with the 95% CI comparing patients treated in the procalcitonin (PCT) and the control groups (Control). Events, number of deceased patients in group; Experimental, PCT group; Total, number of all patients in group; W, weight of individual studies (in fixed- and random-effects model).](cc13157-3){#F3}

The 28-day mortality was covered in four studies \[[@B27],[@B29],[@B30],[@B32]\]. The combined estimate of the RR based on the fixed-effect model for 28-day mortality is 1.02 (95% CI: 0.85; 1.23) (Figure [4](#F4){ref-type="fig"}), again, with no difference between the PCT-guided therapy and standard care group. The test of heterogeneity showed no significant heterogeneity between these studies (*Q* = 1.74; df = 3; *I*^2^ = 0%; tau^2^ = 0; *P* = 0.6287).

![**Forest plot - 28-day mortality.** The forest plot represents the relative risk (RR) together with the 95% CI comparing patients treated in the procalcitonin (PCT) and the control groups (Control). Events, number of deceased patients in group; Experimental, PCT group; Total, number of all patients in group; W, weight of individual studies (in fixed- and random-effects model).](cc13157-4){#F4}

The influential analysis using both the fixed-effect model and the random-effects model showed that no study had great impact on the overall results of hospital mortality and 28-day mortality, respectively.

### Secondary outcomes

The duration of antimicrobial therapy in severe sepsis patients was documented in five studies \[[@B26]-[@B28],[@B30],[@B31]\]. In one study we could only include the subgroup of septic patients with positive blood cultures for assessment of this outcome \[[@B27]\]. The combined estimate for the duration of antimicrobial therapy assessed as the HR and based on the fixed-effect model amounted to 1.27 (95% CI: 1.01; 1.53) (Figure [5](#F5){ref-type="fig"}). These results indicate a significantly shorter median duration of antimicrobial therapy with PCT-guided therapy compared to standard therapy. No significant heterogeneity could be detected between these studies (*Q* = 1.92; df = 4; I^2^ = 0%; tau^2^ = 0; *P* = 0.7499).

![**Forest plot - duration of antimicrobial therapy.** The forest plot represents the hazard ratios (HRs) together with the 95% CIs comparing patients treated in the procalcitonin (PCT) and the control groups. SE, standard error; W, weight of individual studies (in fixed- and random-effects model).](cc13157-5){#F5}

The length of stay in the ICU (ICU-LOS) was documented in five studies \[[@B26],[@B28],[@B30]-[@B32]\]. Additionally, information on ICU-LOS for the subgroup of patients with severe sepsis of the study from Jensen *et al*. \[[@B29]\] was available by correspondence (median ICU-LOS of 6 days in the PCT group versus 5 days in the control group). The combined estimate for ICU-LOS assessed as the HR and based on the fixed-effect model is 0.93 (95% CI: 0.80; 1.06) (Figure [6](#F6){ref-type="fig"}). No significant heterogeneity was detected between these studies (*Q* = 7.98; df = 5; *I*^2^ = 37.3%; tau^2^ = 0.0227; *P* = 0.1575).

![**Forest plot - length of stay in the ICU.** The forest plot represents the hazard ratios (HRs) together with the 95% CIs comparing patients treated in the procalcitonin (PCT) and the control groups. SE, standard error; W, weight of individual studies (in fixed- and random-effects model).](cc13157-6){#F6}

The length of hospital stay was reported in two studies \[[@B26],[@B30]\]. In addition we obtained the median hospital stay for the subgroup of patients with severe sepsis of the study from Jensen *et al*. \[[@B29]\] by correspondence with the author (23 days in the PCT group versus 22 days in the control group). The combined estimate assessed by the HR and fixed-effect model amounted 1.00 (95% CI: 0.84; 1.17) (Figure [7](#F7){ref-type="fig"}). No significant heterogeneity was detected between these studies (*Q* = 2.22; df = 2; *I*^2^ = 10%; tau^2^ = 0.0069; *P* = 0.3292).

![**Forest plot - length of stay in the hospital.** The forest plot represents the hazard ratios (HRs) together with the 95% CIs comparing patients treated in the procalcitonin (PCT) and the control groups. SE, standard error; W, weight of individual studies (in fixed- and random-effects model).](cc13157-7){#F7}

The influential analysis using the fixed-effect model showed no predominant influence on the combined HR of duration of antimicrobial therapy in any study. As shown in the influential analyses based on the fixed-effect model, the study from Jensen *et al*. had great influence on the combined estimates of ICU-LOS and length of hospital stay, respectively. When omitting this study, the results show a trend towards shorter ICU-LOS (HR: 1.19; 95% CI: 0.93; 1.44) and hospital stay (HR: 1.30; 95% CI: 0.87; 1.74) with PCT-guided therapy.

We did not detect significant heterogeneity among these studies and therefore did not perform a meta-regression analysis. Furthermore, the data basis for a meta-regression is rather small.

Discussion
==========

Our meta-analysis aimed to investigate the impact of a PCT-guided therapy compared to standard treatment administered to severe sepsis patients treated in an ICU. Contrary to previous reviews that analyzed patients in various settings with different disease severities, we focused on patients with severe sepsis, a population in which clinical decision-making to stop antibiotic treatment is challenging. In view of the high mortality rate in severe sepsis, clinicians believe themselves to "be on the safer side" with more prolonged courses of antimicrobial treatment. Current evidence to limit duration of antibiotic treatment to 7 to 10 days is rather low and has been included only as a grade-2C recommendation in the recent guidelines of the Surviving Sepsis Campaign \[[@B35]\], in which the authors state that "decisions to continue, narrow, or stop antimicrobial therapy must be made on the basis of clinician judgment and clinical information". Variance of treatment regimens in the control groups of our meta-analysis might therefore reflect the current way of treatment of patients with severe sepsis.

Our findings do not show a significant difference between a PCT-guided therapy and standard care treatment regarding 28-day or hospital mortality, respectively. Furthermore, length of stay in the ICU and in-hospital stay were not different between both groups. However, we found a significant reduction of the length of antibiotic therapy in favor of a PCT-guided therapy strategy. Our calculations, based on the exponential model, indicate a median length of antibiotic treatment of 6 days in the PCT-guided group compared to 8 days in the control group, resulting in a median reduction of approximately 2 days. A reduction of antimicrobial therapy using biomarkers for clinical decision-making may have certain advantages, as antimicrobial resistance becomes more prevalent by using prolonged courses of broad-spectrum antimicrobial agents for treatment of severe sepsis patients \[[@B36],[@B37]\]. Moreover, antibiotic consumption and acquired antimicrobial resistance had been shown to be associated with increased mortality, morbidity, length of hospitalization, and health care costs \[[@B38],[@B39]\].

Currently, no treatment algorithms for guidance of severe sepsis treatment using PCT levels are well established in this high-risk population. To establish a PCT-guided treatment algorithm in severe sepsis patients, it is important to distinguish between escalation and de-escalation of therapeutic interventions. Reliable cut-off values of PCT levels to guide therapeutic decisions need to be defined in future studies, since treatment algorithms varied substantially between the studies included in our systematic review. For instance, Annane *et al*. and Bouadma *et al*. \[[@B26],[@B27]\] encouraged a prolongation of antibiotic treatment if PCT levels were above 0.5 ng/mL, and discouraged antibiotic treatment if levels dropped below 0.5 ng/mL. Furthermore, Annane *et al*. distinguished between medical and surgical patients. In surgical patients a different algorithm was applied with a recommendation to stop antibiotics when PCT levels were below 4 ng/mL. Bouadma *et al*. recommended stopping antibiotics at PCT levels below 0.25 ng/mL. If PCT levels were between 0.5 ng/mL and 0.25 ng/mL, antibiotics were stopped if there was a decrease of at least 80% of the peak concentration of PCT levels. Four studies recommended a PCT level of 1.0 ng/mL as the cutoff \[[@B28]-[@B31]\]. Hochreiter *et al*. and Schroeder *et al*. recommended discontinuing antibiotics if PCT was below 1.0 ng/mL. Both recommended to discontinue antibiotics if PCT levels dropped by 35% of the initial level within 3 days. Nobre *et al*. recommended discontinuing antibiotics in patients with PCT levels below 0.1 ng/mL after 3 days. In patients with PCT levels above 1.0 ng/mL antibiotics were discontinued if PCT levels dropped more than 90% from the baseline peak level or if PCT levels were below 0.25 ng/mL after 5 days.

In contrast to all other studies, Jensen *et al*. tested a rigorous escalation strategy \[[@B29]\]. In the case of PCT levels above 1.0 ng/mL an intensified antibiotic treatment strategy was recommended. De-escalation was only possible if PCT levels dropped below 1.0 ng/mL for at least 3 days. This treatment algorithm led to a prolonged length of stay in the ICU and substantially higher use of broad-spectrum antimicrobials. A different cut-off level of 2.0 ng/mL was used by Svoboda *et al*. in surgical patients \[[@B32]\].

This meta-analysis has several limitations. First, studies included in our meta-analysis varied substantially in study design and objectives. Two studies provided rules for starting or continuing as well as discontinuing antibiotic treatment \[[@B26],[@B27]\]. Three studies focused on de-escalation of antibiotic therapy \[[@B28],[@B30],[@B31]\], whereas two studies placed the focus on escalation of antibiotic treatment and diagnostic efforts \[[@B29],[@B32]\] and surgical treatment \[[@B32]\]. Second, a limited number of patients is included, third, a combined analysis of medical and surgical patients is problematic, since there are substantial differences in outcomes regarding surgical patients, where surgical source-control measures play a dominant role.

In order to explore knowledge on a PCT-guided treatment in severe sepsis patients in more detail, we await the results of seven ongoing studies registered at <http://www.ClinicalTrials.gov> that might deliver important results for future systematic reviews.

Conclusion
==========

An approach along a biomarker-guided treatment algorithm using procalcitonin levels may be helpful to guide antimicrobial treatment in severe sepsis patients, treated in ICUs and reduces the duration of antimicrobial therapy without an obvious increase in mortality. However, more research is urgently needed to investigate the safety and effectiveness in subgroups of surgical and medical severe sepsis patients, treated in ICUs. Most importantly, treatment algorithms differ substantially and have to be clarified in future studies.

Key messages
============

• A PCT-guided treatment reduces the duration of antimicrobial therapy in severe sepsis patients, without increasing 28-day and in-hospital mortality rates

• Recommendations for PCT-guided treatment algorithms for treatment of severe sepsis patients differ substantially among published studies

• Future studies have to show which PCT-guided treatment algorithms could be recommended in severe sepsis patients
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